Replimune Group (REPL) News Today

Replimune Group, Inc. (NASDAQ: REPL) is seeing mixed investor reactions after receiving FDA approval for its first commercial product, while renewed securities-fraud litigation and concerns stemming from the drug’s regulatory history weigh on sentiment.

• Positive Sentiment: The FDA granted accelerated approval to Tudriqev (RP1/vusolimogene oderparepvec) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed after an anti-PD-1-based treatment. The approval gives Replimune its first marketed product and creates a potential commercial revenue opportunity. Reuters FDA approval article
• Positive Sentiment: JPMorgan raised its price target on Replimune from $17 to $20 and maintained an “overweight” rating, indicating analysts see substantial upside from the company’s newly commercialized therapy. Benzinga price target report
• Positive Sentiment: Call-option activity was unusually high, with investors purchasing 25,580 calls—nearly double the average daily volume—suggesting increased speculative bullish positioning, although options activity does not guarantee further gains.

• Neutral Sentiment: The FDA approval came on Replimune’s third attempt after two prior rejections related to clinical data-quality concerns. While the decision removes a major regulatory hurdle, the accelerated approval likely leaves investors focused on confirmatory studies, launch execution and the size of the eligible melanoma market. Wall Street Journal FDA approval article

• Negative Sentiment: Shares have decreased despite the approval, reflecting a possible “sell-the-news” reaction and lingering concerns about the product’s regulatory and clinical history.
• Negative Sentiment: Several law firms announced or promoted securities-fraud class actions covering investors who bought Replimune securities between October 20, 2025, and April 10, 2026. The complaints allege Replimune failed to disclose FDA study-design concerns and relied on limited, early data. The allegations remain unproven, but the litigation adds legal costs, reputational risk and an overhang for investors. Replimune class action notice